| 产品描述: | Wnt/β-连环蛋白激动剂;Wnt/beta-catenin Agonists;;InformationWAY-262611 WAY-262611 (BML-WN110, Compound 5) is a beta-catenin (β-Catenin) agonist that increases bone formation rate with EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also an inhibitor of dickkopf 1 (DKK1) .TargetsDKK1 ; β-Catenin (TCF-Luciferase assay) ; 0.63 μM(EC50)In vitroWAY-262611, the DKK1 inhibitor, blocks DKK1 and restores the GDF5 reduced MMP13 gene expression.In vivoWAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration.Cell Research(from reference)Cell lines:Surplus human chondrocytes Concentrations:0.01 μM, 0.1 μM, 1 μM Incubation Time:21 days |
| 靶点: |
EC50: 0.63 μM (β-Catenin) |
| 体内研究: |
WAY-262611 具有出色的药代动力学特性,口服给药后,卵巢切除大鼠的骨小梁形成率呈剂量依赖性增加。用 WAY-262611 处理的 wt 小鼠的颅骨显示出统计上增加的 BFR,而类似处理的 KO 动物与对照没有区别。这表明 WAY-262611 通过 Wnt β-catenin 通路发挥作用,很可能是通过抑制 Dkk-1 发挥作用。 |
| 参考文献: |
1. Pelletier JC, et al. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem. 2009 Nov 26;52(22):6962-5. 2. L Enochson, et al. GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthritis Cartilage. 2014 Apr;22(4):566-77. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.141 ml |
15.703 ml |
31.405 ml |
| 5 mM |
0.628 ml |
3.141 ml |
6.281 ml |
| 10 mM |
0.314 ml |
1.57 ml |
3.141 ml |
| 50 mM |
0.063 ml |
0.314 ml |
0.628 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |